Health officials in the United Kingdom are responding to a growing outbreak of meningitis B, prompting warnings for students, families, and the wider public to stay alert to symptoms and vaccination guidance.
The outbreak, centered in Canterbury, Kent, has resulted in around 29 confirmed and probable cases and at least two deaths, according to the UK Health Security Agency (UKHSA). Many of the infections are linked to schools, universities, and a nightclub event identified as a likely transmission cluster.
Meningitis B is caused by the bacterium Neisseria meningitidis and can lead to inflammation of the brain and spinal cord or severe bloodstream infection. The illness can progress rapidly and become life-threatening within hours if not treated promptly.
Health authorities say the overall risk to the wider public remains low, but close contacts of infected individuals are being offered antibiotics and vaccinations to prevent further spread. More than 2,000 people have already received vaccines as part of targeted response efforts.
Symptoms to watch for include fever, severe headache, stiff neck, sensitivity to light, vomiting, confusion, and a rash that does not fade under pressure. Early treatment with antibiotics is critical and can significantly improve survival chances.
The MenB vaccine, commonly known as Bexsero, has been confirmed to protect against the strain involved in the outbreak, offering reassurance to those eligible for immunisation.
While meningitis B cases are relatively rare overall, adolescents and young adults—especially those living in shared accommodation—face higher risk. Officials are urging anyone with symptoms to seek immediate medical help and encouraging eligible individuals to consider vaccination.
Experts say rapid awareness, early treatment, and targeted immunisation remain the most effective tools to control the outbreak and prevent additional infections.
